Tempus AI, Inc. (TEM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance
Tempus AI continues strong revenue growth, driven by its high-margin Data and Services segment and recent Ambry acquisition, but profitability remains elusive. Operational progress is evident, with expanding pharma partnerships and a growing AI-driven data platform, yet financial risks persist due to high cash burn and new debt. Upcoming Q2 results will be critical to assess sustainable profitability, margin stability, and growth in high-value contracts and test reimbursement rates.
Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships
I am strongly bullish on Tempus AI due to its strategic partnerships, Ambry Genetics acquisition, and leadership in AI-driven precision oncology. Tempus' collaborations and acquisitions position it at the forefront of a rapidly growing oncology market, with an expected 80% revenue growth in 2025. Despite current net losses from high R&D, I project breakeven soon and a price target of $124 by 2029, a 91% upside.
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?
Tempus AI and Recursion Pharmaceuticals are fine ways to play the AI revolution from the health angle.
Tempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum
TEM secures FDA clearance for its AI-powered ECG tool targeting heart failure, as AI ECG adoption accelerates.
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?
TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.
Tempus AI Raises 2025 Financial Outlook: What's Backing It?
TEM lifts its 2025 revenue and EBITDA outlook on strong Q1 results, key partnerships and testing expansion.
What's Fueling Tempus AI's Explosive Sales Growth?
TEM's Q1 revenues jump 75.4%, powered by soaring genomics sales, strategic deals and new test launches.
Tempus AI: High-Growth And High-Risk
Tempus AI offers a compelling vision in precision oncology, boasting strong data assets, strategic partnerships, and rapid revenue growth. Valuation is rich, and execution risk is high—success depends on converting AI promise into validated, reimbursed diagnostics and sustainable cash flow. Tempus is a high-risk, high-reward play; I rate it a Hold, suitable only for speculative investors with a long-term, risk-tolerant outlook.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Tempus AI Is Well Worth Its Price Tag
Tempus AI's innovation in genomics, data, and applications makes the company well positioned to become a contender in the AI healthcare space. Strong innovation is clearly translating into their financial metrics as revenue growth and margin expansion are promising signs. Guidance was strong as revenue growth is expected to accelerate and the company expects to be adjusted EBITDA positive this year.
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?
GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.
